Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin step-down versus continued carbapenem for ESBL Enterobacteriaceae urinary tract infection after discharge
IRCT20191104045328N3Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fosfomycin in urinary tract infection (UTI) (3 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Urine culture, Urinary symptoms and 2 more. Started Dec 2019; status: completed.
02
Drugs
fosfomycin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on IRCT20191104045328N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N3.